Physician profile
Gary I Gorodokin
NPI 1619996774
$12,986.91
in general payments reported to CMS, 2019-2025
27 companies · $263 in 2025
The $263 reported for 2025 was less than what a typical Gastroenterology (Internal Medicine) provider received nationally (typical 2025 total: $636).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,106 · 2020: $3,579 · 2021: $3,793 · 2022: $1,109 · 2023: $2,838 · 2024: $298 · 2025: $263.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $2,400 · Food and Beverage: $1,000.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $2,400.00 |
| Food and Beverage | $1,000.05 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $4,626.43 | 2019-2024 | |
| Redhill Biopharma INC. | $4,567.44 | 2020-2024 | Talicia, Aemcolo |
| Salix Pharmaceuticals, A Division of Bausch Health US, LLC | $692.90 | 2019-2024 | Trulance |
| Ironwood Pharmaceuticals, INC | $650.35 | 2019-2025 | Linzess |
| Takeda Pharmaceuticals U.S.A., INC. | $503.97 | 2019-2025 | Entyvio |
| Madrigal Pharmaceuticals | $306.82 | 2024-2025 | Rezdiffra |
| Allergan, INC. | $302.06 | 2019 | |
| Gilead Sciences, INC. | $270.54 | 2019-2022 | |
| Janssen Biotech, INC. | $149.52 | 2021-2023 | Stelara |
| Shionogi INC | $135.87 | 2019 | |
| Astrazeneca Pharmaceuticals LP | $124.98 | 2022 | |
| E.R. Squibb & Sons, L.L.C. | $124.98 | 2022 | |
| Ardelyx, INC. | $72.57 | 2022-2025 | Ibsrela |
| Nestle Healthcare Nutrition INC. | $51.54 | 2021-2023 | |
| Braintree Laboratories, INC. | $47.69 | 2021-2025 | Suflave |
Show all 27 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Intercept Pharmaceuticals, INC. | $42.29 | 2020-2022 | |
| Celgene Corporation | $41.66 | 2021-2022 | |
| Concordia Pharmaceuticals INC. | $38.70 | 2019 | |
| Intra-Sana Laboratories | $37.46 | 2022 | |
| Celltrion USA INC. | $34.85 | 2024 | Vegzelma |
| Qol Medical, LLC | $32.89 | 2025 | Sucraid |
| Almatica Pharma LLC | $31.85 | 2021 | |
| Phathom Pharmaceuticals, INC. | $27.14 | 2024 | Voquezna |
| Daiichi Sankyo INC. | $24.10 | 2020 | |
| Ferring Pharmaceuticals INC. | $21.43 | 2022 | |
| Pfizer INC. | $14.82 | 2023 | |
| Merck Sharp & Dohme LLC | $12.06 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Gary Gorodokin listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.